SSanofi Read More Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?June 22, 2026 Sanofi’s SNY Dupixent, which it co-develops with Regeneron REGN, is its key top-line driver. The drug has transformed the treatment…
